UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The Securities Exchange Act of 1934~~

~~Date~~The ofSecurities ~~Report~~Exchange ~~(Date~~Act of ~~earliest~~ ~~event reported): July 27, 2005~~1934

Date of Report (Date of earliest event reported): December 14, 2005

INAMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	1-9741	59-0920629
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction	(Commission	(IRS Employer
5540 Ekwill Street Santa Barbara, California		93111-2936
of incorporation)	File Number)	Identification No.)
5540 Ekwill Street
Santa Barbara, California		93111-2936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (805) 683-6761

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o ý Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 28.0201 ~~Results~~– ofOther ~~Operations and Financial Condition~~Events.

On ~~July~~December 2715, 2005, Inamed Corporation (~~the~~ “~~Company~~Inamed”) issued a press release announcing that on December 14, 2005 its Board of ~~financial~~Directors ~~results~~unanimously ~~for~~approved the ~~second~~definitive ~~fiscal~~Agreement ~~quarter~~and ~~ended~~Plan ~~June~~of Merger (the “Merger Agreement”) between Inamed and Allergan, 30Inc. (“Allergan”) previously executed and delivered by Allergan on December 6, 2005. However, Inamed has not yet signed the Merger Agreement. This approval was conducted in accordance with the terms of the irrevocable offer letter delivered to Inamed by Allergan on December 6, 2005. A copy of the press release is ~~attached~~ attached hereto as Exhibit 99.1, and copies of the Merger Agreement and the irrevocable offer letter have previously been filed as exhibits to Inamed’s Schedule 14d-9/A filed with the U.S. Securities and Exhchange Commission on December 6, 2005.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(cd) Exhibits.

99.1 Press Release of Inamed Corporation, dated ~~July 27~~December 15, 2005.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INAMED CORPORATION
Date: July 27, 2005	By:	/s/ Declan Daly
Date: December 15, 2005
		Declan Daly
	By:	/s/ Joseph A. Newcomb
		Executive Vice President and Chief Financial Officer
		Joseph A. Newcomb
		Executive Vice President, Secretary and General
		Counsel

Filing Compare · INAMED CORP